Touchstone
Last syncNov 1, 2026, 6:55 PM ET

RPRX

Royalty Pharma Plc Health Care Pharmaceutical Preparations Russell 3000
$67.18Close $36.24 – $67.1852-week range Nov 4, 2026Next report · before the open

Highlights

Strengths

  • In a stage-2 uptrend all 8 trend conditions pass
  • Leading the market RS 92 · stronger than 92% of stocks over 12 months
  • RS line at a 1-year high outperforming the S&P 500 more than at any point this year
  • Near its high at its 52-week high

Cautions

  • Extended 5.4 ATR above its 50-day average
  • Earnings shrinking EPS −44% year on year
  • Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 5, 2026
Off 12-month high 0%
1wk up 5.2% price change
1mo up 15.1% price change
12-month return up 85% market up 11% · its own up 76%
F-score — — Not assessed
Altman Z — Unknown
P/E — price / earnings
PEG — P/E / EPS growth
P/B — price / book
Earnings yield — EBIT / enterprise value
Cheaper than — of the market · not assessed
Revenue growth up 5% year on year
EPS growth down 44% latest quarter · -72 pts
Sales growth up 16% latest quarter · +6 pts
ROE up 8% return on equity
Free cash margin up 105% $2.5B FCF
D/E 0.88 long-term debt / equity
Net debt / EBITDA 5.1×
Interest cover —EBIT / interest
Piotroski tests

Repair signals

  • Revenue reaccelerating (-4% then +5%)

Trade setup

ATR% 2.1% $1.42 a day · 2×ATR $64.34
RS 92 / 99 vs the universe
Trend 8 / 8 trend template
Relative volume 1.5× vs 50-day average
Up/down volume 1.42 50 sessions
Implied move — no option chain · report Nov 4, 2026
Trend template · 8 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged
  • Heavily indebted Net debt is 5.1 times EBITDA — roughly 5 years of earnings before interest, tax and depreciation to repay borrowings in full.
Last reported Aug 5, 2026
Results reaction Aug 5, 20260% vs market2 sessions after results

Financials

6 fiscal years · from filings
Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $2.4B +5% on FY2024
$0 $2.5B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $2.1B FY2021 · $2.3B FY2022 · $2.2B FY2023 · $2.4B FY2024 · $2.3B FY2025 · $2.4B
Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology $770.9M -10% on FY2024
$0 $2B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $975.0M FY2021 · $619.7M FY2022 · $42.8M FY2023 · $1.1B FY2024 · $859.0M FY2025 · $770.9M
Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $2.5B -10% on FY2024
$0 $5B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · $2.0B FY2021 · $2.0B FY2022 · $2.1B FY2023 · $3.0B FY2024 · $2.8B FY2025 · $2.5B
Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology
  • Net 32%
  • Free cash 105%
0% 200% FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Net 46% · Free cash 96% FY2021 · Net 27% · Free cash 88% FY2022 · Net 2% · Free cash 96% FY2023 · Net 48% · Free cash 127% FY2024 · Net 38% · Free cash 122% FY2025 · Net 32% · Free cash 105%
Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $8.0B net debt
  • Cash
  • Long-term debt
$0 $10B FY20 FY21 FY22 FY23 FY24 FY25 FY2020 · Cash $1.0B · Long-term debt $5.8B FY2021 · Cash $1.5B · Long-term debt $7.1B FY2022 · Cash $1.7B · Long-term debt $6.1B FY2023 · Cash $477.0M · Long-term debt $6.1B FY2024 · Cash $929.0M · Long-term debt $6.6B FY2025 · Cash $618.7M · Long-term debt $8.6B
  FY2020Dec 31, 2020 FY2021Dec 31, 2021 FY2022Dec 31, 2022 FY2023Dec 31, 2023 FY2024Dec 31, 2024 FY2025Dec 31, 2025
Revenue $2.1B $2.3B $2.2B $2.4B $2.3B $2.4B
Operating income $1.6B $1.4B $307.1M $1.5B $1.3B $1.6B
Net income $975.0M $619.7M $42.8M $1.1B $859.0M $770.9M
Net margin 46% 27% 2% 48% 38% 32%
Earnings per share $2.60 $1.49 $0.10 $1.88 $1.45 $1.37
Free cash flow $2.0B $2.0B $2.1B $3.0B $2.8B $2.5B
Free cash margin 96% 88% 96% 127% 122% 105%
Cash $1.0B $1.5B $1.7B $477.0M $929.0M $618.7M
Long-term debt $5.8B $7.1B $6.1B $6.1B $6.6B $8.6B
Shareholders' equity $9.9B $10.2B $9.5B $10.1B $10.3B $9.7B

Filings

SEC EDGAR
FiledReportPeriod to Lag
Aug 5, 2026 Quarterly ↗ Jun 30, 2026 36d
May 6, 2026 Quarterly ↗ Mar 31, 2026 36d
Feb 11, 2026 Annual ↗ Dec 31, 2025 42d
Nov 5, 2025 Quarterly ↗ Sep 30, 2025 36d
Aug 6, 2025 Quarterly ↗ Jun 30, 2025 37d
May 8, 2025 Quarterly ↗ Mar 31, 2025 38d
Feb 12, 2025 Annual ↗ Dec 31, 2024 43d
Nov 6, 2024 Quarterly ↗ Sep 30, 2024 37d
Aug 8, 2024 Quarterly ↗ Jun 30, 2024 39d
May 9, 2024 Quarterly ↗ Mar 31, 2024 39d
Feb 15, 2024 Annual ↗ Dec 31, 2023 46d
Nov 8, 2023 Quarterly ↗ Sep 30, 2023 39d

Current reports

FiledDisclosed
Aug 5, 2026 Results ↗
Jun 4, 2026 Shareholder vote ↗
May 28, 2026 Material agreement · New obligation ↗
May 6, 2026 Results ↗
Apr 13, 2026 Regulation FD ↗
Feb 11, 2026 Results ↗
Dec 22, 2025 Director or officer change ↗
Dec 22, 2025 Regulation FD ↗
Nov 5, 2025 Results ↗
Sep 16, 2025 Material agreement · Other events ↗
Aug 13, 2025 Director or officer change ↗
Aug 6, 2025 Results ↗